White House drug czar Sara Carter said the U.S. is working to save American lives by targeting drug cartels and curbing opioids [1, 2].
The strategy addresses a growing substance-use disorder crisis that threatens public safety and increases overdose deaths across the country [2, 3].
Carter, the Director of the Office of National Drug Control Policy (ONDCP), has focused on the severity of the drug crisis in several public forums this year. During a televised interview on "My View with Lara Trump," she highlighted the human cost of the epidemic. "We're losing real people who have suffered," Carter said [1].
Beyond fentanyl, Carter said other synthetic substances are entering the supply. She specifically noted that a deadly "rhino tranquilizer" is killing Americans [2]. To combat these threats, the administration is focusing on disrupting the cartel-sponsored trafficking networks that facilitate the flow of these drugs into the U.S. [2, 3].
In addition to enforcement, the administration is integrating healthcare with social services. In April 2026, Carter hosted a summit at the White House to discuss best practices for addiction treatment within the homeless population [3]. During that event, she announced a two-phase initiative designed to provide specialized addiction treatment for those experiencing homelessness [3].
Carter has also taken these policy discussions to the regions most affected by the crisis. On May 1, 2026, she participated in a roundtable in Charleston, West Virginia, to discuss federal interventions and local needs [4].
The administration's approach combines aggressive law enforcement against international cartels with a targeted domestic health strategy to treat vulnerable populations [2, 3].
“"We're losing real people who have suffered."”
The Trump administration is pursuing a dual-track strategy that treats the drug crisis as both a national security threat and a public health emergency. By combining cartel disruption with specialized treatment for the homeless, the ONDCP is attempting to shrink the drug supply while simultaneously reducing the demand among the most marginalized populations.
